drugset / Trial / NCT01052012
Bupivacaine Effectiveness and Safety in SABER® Trial
Phase 3
Completed
331 enrolled
Durect
Hospira, now a wholly owned subsidiary of Pfizer · collabNycomed · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local post-surgical pain. The purpose of this study is to investigate safety (side effects) associated with the use of SABER-Bupivacaine and how well it works in reducing pain and opioid-related side effects following various kinds of abdominal surgeries.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | — | — |
Indications
No indication recorded.